Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
Vaccine
; 41(4): 938-944, 2023 01 23.
Article
en En
| MEDLINE
| ID: mdl-36585278
ABSTRACT
Malaria kills around 409,000 people a year, mostly children under the age of five. Malaria transmission-blocking vaccines work to reduce malaria prevalence in a community and have the potential to be part of a multifaceted approach required to eliminate the parasites causing the disease. Pfs25 is a leading malaria transmission-blocking antigen and has been successfully produced in a plant expression system as both a subunit vaccine and as a virus-like particle. This study demonstrates an improved version of the virus-like particle antigen display molecule by eliminating known protease sites from the prior A85 variant. This re-engineered molecule, termed B29, displays three times the number of Pfs25 antigens per virus-like particle compared to the original Pfs25 virus-like particle. An improved purification scheme was also developed, resulting in a substantially higher yield and improved purity. The molecule was evaluated in a mouse model and found to induce improved transmission-blocking activity at lower doses and longer durations than the original molecule.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Malaria Falciparum
/
Vacunas contra la Malaria
/
Malaria
Tipo de estudio:
Risk_factors_studies
Límite:
Animals
Idioma:
En
Revista:
Vaccine
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos